Otezla improves quality of life in psoriasis patients

[Fred]

More good news for New psoriasis tablet Otezla (Apremilast) has been announced at the European Academy of Dermatology and Venereology congress in Amsterdam.

Quote:

---

New analysis of the ESTEEM 2 trial, demonstrated that more than 70% of patients who received treatment with Otezla (apremilast) twice-daily after 16 weeks achieved clinically meaningful improvement when rated by the Dermatology Quality of Life Index.

Pooled analyses of ESTEEM 1 and 2 from 1,250 patients was also presented, showing that Otezla significantly increased work productivity and improved work limitations compared with placebo at week 16. Other data, from ESTEEM 2, demonstrated that the phosphodieasterase-4 (PDE-4) inhibitor significantly improved psoriasis in difficult-to-treat areas such as the palms of the hands and feet, nails and scalp.

Otezla is competing with the injectable tumour necrosis factor (TNF) inhibitors, notably AbbVie's Humira (adalimumab) and Pfizer/Amgen's Enbrel (etanercept). Many observers believe the fact that it does not require routine lab monitoring is a significant plus, while Lluis Puig of Hospital de la Santa Creu i Sant Pau in Barcelona, speaking at an event outside EADV, said oral treatments could be a better long-term option.

Source: NO LINKS ALLOWED

More on Otzela:
Otezla gets FDA approval for Psoriatic Arthritis
Apremilast first phase 3 results

More about the Dermatology Life Quality Index (DLQI)